. Author manuscript; available in PMC: 2013 Oct 1.

Published in final edited form as: Curr Psychiatry Rep. 2012 Oct;14(5):469–477. doi: 10.1007/s11920-012-0300-0

Table 2.

Summary of medication trials for PTSD-SUD

Authors	Sample	n	Active group (s)	Control group	Main findings
Alderman et al. [63]	Male combat veterans	43	Topiramate	None	- Significant reduction in PTSD symptoms
Alderman et al. [63]	Male combat veterans	43	Topiramate	None	- No reduction in drinking behavior
Brady et al. [61]	Individuals recruited through the community and outpatient SUD treatment	94	Sertraline	Placebo	- No significant group differences in alcohol consumption or PTSD symptoms
Petrakis et al. [62]	Veterans attending outpatient VA clinics	93	(1) Naltrexone + placebo	Placebo	- Active conditions related to equal improvements in SUD outcomes (fewer drinking days, longer abstinence)
			(2) Disulfiram + placebo		- Active conditions related to improvements in PTSD symptoms
			(3) Naltrexone + disulfiram		- Disulfiram and naltrexone less effective for PTSD when administered in combination with one another
Petrakis et al. [64]	Primarily male veterans	88	(1) Paroxetine + naltrexone	No inactive control condition	- Paroxetine and desipramine related to equivalent reductions in PTSD symptoms
			(2) Paroxetine + placebo		- Desipramine related to fewer heavy drinking days
			(3) Desipramine + naltrexone		- No effect observed for naltrexone
			(4) Desipramine + placebo